deltatrials
Unknown OBSERVATIONAL NCT00386737

Development of a Breath Analyzer for Asthma Screening

Sponsor: American Lung Association

Conditions Asthma
Updated 6 times since 2017 Last updated: Oct 11, 2006 Started: Sep 30, 2004 Completion: Feb 28, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Asthma, this trial is ongoing. The trial is conducted by American Lung Association and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

The study plan is divided into two sections: in-clinic studies and large-scale outreach screening. (A). Clinical Studies The clinical study is intended to obtain data characterizing eNO concentrations within individual groups of subjects listed in the inclusion criteria. The type of this study is "non-invasive", and the study design is "diagnosis/ treatment monitoring, and efficacy". The study will seek to recruit subjects who fall into one of the categories listed in the inclusion criteria below. The number of subjects (n) to be recruited for each category is given and is estimated based on the past number of subjects mainly at the Ekips Technologies, The Oklahoma Allergy \& Asthma Clinic, and the Norman Lung Center sites. Inclusion Criteria (Total Number of Subjects, n = 700) Both genders are eligible for this study: 1. Healthy subjects (n=120) 2. Asthma (Total n=450) \[diagnosed according to NHLBI/ NAEPP Guidelines (1998)\] 1. Non-treated or B2-agonist treated asthmatics (n=150), 2. Glucocorticoid treated asthmatics, (n=150), 3. Leukotriene Antagonist treated asthmatics, (n=75), 4. Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75). 3. Acute respiratory illnesses (n=65 a) Sinusitis (Acute and Chronic), b) Influenza, c) Common cold, d)Pneumonia, e)Related symptoms, but no diagnosis. 4. Allergies (n=65) a) Atopic dermatitis,...

The study plan is divided into two sections: in-clinic studies and large-scale outreach screening.

(A). Clinical Studies The clinical study is intended to obtain data characterizing eNO concentrations within individual groups of subjects listed in the inclusion criteria. The type of this study is "non-invasive", and the study design is "diagnosis/ treatment monitoring, and efficacy". The study will seek to recruit subjects who fall into one of the categories listed in the inclusion criteria below. The number of subjects (n) to be recruited for each category is given and is estimated based on the past number of subjects mainly at the Ekips Technologies, The Oklahoma Allergy \& Asthma Clinic, and the Norman Lung Center sites.

Inclusion Criteria (Total Number of Subjects, n = 700)

Both genders are eligible for this study:

1. Healthy subjects (n=120) 2. Asthma (Total n=450) \[diagnosed according to NHLBI/ NAEPP Guidelines (1998)\]

1. Non-treated or B2-agonist treated asthmatics (n=150), 2. Glucocorticoid treated asthmatics, (n=150), 3. Leukotriene Antagonist treated asthmatics, (n=75), 4. Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75). 3. Acute respiratory illnesses (n=65

a) Sinusitis (Acute and Chronic), b) Influenza, c) Common cold, d)Pneumonia, e)Related symptoms, but no diagnosis. 4. Allergies (n=65) a) Atopic dermatitis, b) Allergic rhinitis, c) Seasonal allergies.

Healthy Subjects Recruiting

Healthy subjects will be recruited from visitors and patients at the study sites. Visitors may include relatives or friends accompanying patients. Healthy employees at the study sites may be asked to participate in the study. Patients, visitors, and employees will be told that do not have to participate if they do not want to.

Exclusion Criteria

Subjects younger than 4 and older than 65 will be excluded from the study. Pregnant women will also be excluded from the study.

Duration of Participation

For each visit, the participant in the study will be asked to donate up to 3 breath samples for the first visit. The total time required for breath donations and measurements will be about 5 minutes. An additional five minutes of a subject's time are needed to complete a short interview if the information needed is not already available.

Asthmatic or suspected asthmatic patients, both treated and non-treated will be asked to donate breath during additional visits if convenient. Follow-up measurements may be performed during regularly scheduled office visits.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotUnknown Status~Apr 2018 – ~Jan 2021 · 33 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 19 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown StatusUnknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status

  4. Apr 2018 — Jan 2021 [monthly]

    Unknown Status

    Phase: EARLY_PHASE1None

  5. Feb 2017 — Apr 2018 [monthly]

    Unknown Status EARLY_PHASE1

    Phase: Phase 0EARLY_PHASE1

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Unknown Status Phase 0

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American Lung Association
  • Ekips Technologies
Data source: Ekips Technologies

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations